Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.

Slides:



Advertisements
Similar presentations
Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.
Advertisements

New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.
Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.
A case series of ART-associated gynaecomastia reported to the National HIV & TB Healthcare Workers (HCW) hotline Christine Njuguna. Division of Clinical.
TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.
Impact of tuberculosis screening and isoniazid preventive therapy on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study B. Durovni1,2,
Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Treatment for Adolescents With Depression Study (TADS)
Changes in Lipids in Randomised, Open-Label Comparative Trial of Abacavir or Tenofovir DF as Replacement for a Thymidine Analogue in Persons with Lipoatrophy.
Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.
Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.
Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:
Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.
HIV i-Base: SMART Study & CROI Feedback UK-CAB - Feb 2006 UK-CAB 24 February 2006 CROI Feedback: SMART Study Simon Collins.
Switch NNRTI to NNRTI  Switch EFV to ETR –CNS toxicity study –Patient’s preference study.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.
NIAID ERADICATE Open-label W12 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml.
Maintenance therapy with Trizivir® after 6 months induction with Trizivir® plus either efavirenz or lopinavir/r in naïve patients. Trizefal study J. Mallolas*
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.
Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.
Long-Term Comparison of Nevirapine Versus Efavirenz When Combined with Other Antiretroviral Drugs in HIV-1 Positive Antiretroviral-Naïve Persons- The NNRTI.
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Neurologic Effects Associated With Efavirenz Generally Mild, Transient Slideset on: Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological.
Once-Daily Celecoxib Effective for Preventing Sporadic Colorectal Adenomas Slideset on: Arber N, Rácz I, Spicak J, et al. Chemoprevention of colorectal.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
HIV Infection Increases Risk of ASCUS and Subsequent Development of SILs Slideset on: Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection.
Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Reducing Tobacco Intake Lowers Risk of Lung Cancer in Heavy Smokers Slideset on: Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung.
Rare Cases of Hypokalemia Associated With Tenofovir Use Slideset on: Cirino CM, Kan VL. Hypokalemia in HIV patients on tenofovir. AIDS. 2006;20:
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.
Increasing Tuberculosis Prevalence in South African Township Associated With Increasing HIV Prevalence Slideset on: Lawn SD, Bekker LG, Middelkoop K, Myer.
Tipranavir/Ritonavir Superior to Comparator PI/Ritonavir at Week 48 in Multiclass-Experienced Patients Slideset on: Hicks CB, Cahn P, Cooper DA, et al.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
#AIDS2016 Dolutegravir (DTG) plus Rilpivirine (RPV) in Suppressed Heavily Pretreated HIV-Infected Patients A. Díaz, J.L. Casado, F.
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
undetectable (undetectable-6.25)
Switch to Etravirine from Efavirenz due to CNS Toxicity SSAT-029 STUDY
Switch to DTG-containing regimen
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George.
Switch to LPV/r monotherapy
Switch to RAL-containing regimen
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
Switch to DTG-containing regimen
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Presentation transcript:

Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis. 2006;42:

clinicaloptions.com/hiv Efavirenz Use Not Associated With Depressive Episodes Journot V, et al. Clin Infect Dis. 2006;42: Background and Rationale  Efavirenz frequently causes early, transient CNS adverse reactions  Some reports have associated efavirenz with acute depression and suicidal ideation, especially among patients with history of depression –Other studies found no association  Current study examined efavirenz association with depressive disorders by comparing incidence of disorders between patients switching to efavirenz-based regimen and patients continuing on PI-based regimen

clinicaloptions.com/hiv Efavirenz Use Not Associated With Depressive Episodes Journot V, et al. Clin Infect Dis. 2006;42: Summary of Study Design  Data from patients participating in ALIZE-ANRS 099 –Patients with controlled HIV-1 infection received stable PI- based regimen or switched to once-daily efavirenz, didanosine, and emtricitabine  Depressive symptoms assessed throughout study –Self-administered Centre for Epidemiologic Studies- Depression Scale questionnaire at Weeks 0, 24, 48 –Patients asked every 8 weeks the frequency of depressive mood and suicidal ideation since prior visit –Medical charts reviewed for use of antidepressants at baseline, during study, and during follow-up

clinicaloptions.com/hiv Efavirenz Use Not Associated With Depressive Episodes Journot V, et al. Clin Infect Dis. 2006;42: Baseline Characteristics Characteristic Efavirenz-Based Treatment (n = 178) PI-Based Treatment (n = 177) Median age, yrs (IQR)41 (36-47)41 (35-51) Male, n (%)152 (85)154 (87) AIDS, n (%)50 (28)45 (25) Median CD4+ cell count, cells/mm 3 (IQR)509 ( )547 ( ) History of depressive disorder, n (%)15 (8)16 (9)  Depression, n1513  Suicidal ideation, n10  Suicide attempt, n03 Receipt of antidepressants at baseline, n (%)8 (4)8 (5)

clinicaloptions.com/hiv Efavirenz Use Not Associated With Depressive Episodes Journot V, et al. Clin Infect Dis. 2006;42: Main Findings  No discontinuations caused by depressive episodes  Incidence of depressive episodes, new antidepressant use during study, follow-up comparable between arms  Independent predictors of depressive episode during treatment: –Age, per 10-year decrease (HR, 1.61; 95% CI, ; P =.03) –History of depressive disorders (HR, 4.97; 95% CI, ; P =.0004)

clinicaloptions.com/hiv Efavirenz Use Not Associated With Depressive Episodes Journot V, et al. Clin Infect Dis. 2006;42: Incidence of Depressive Episodes Outcome Efavirenz-Based Treatment (n = 178) PI-Based Treatment (n = 177) Patients experiencing ≥ 1 depressive episode, n (%)15 (8)12 (7) Depressive episode, no. of events1612  Depression1511  Suicide attempt13 Depressive episode event severity, no. of events  Mild33  Moderate116  Severe14  Life threatening11 New use of antidepressants during treatment or follow-up, n (%) 12 (7) (n = 170) 7 (4) (n = 169) Depressive episode incidence/100 patient-years (95% CI) 11 (5-16)9 (4-13)

clinicaloptions.com/hiv Efavirenz Use Not Associated With Depressive Episodes Journot V, et al. Clin Infect Dis. 2006;42: Key Conclusions  No difference in incidence of depressive episodes between NNRTI-naive patients switching to efavirenz- based regimen and those remaining on PI-based regimen  High incidence of depressive episodes among total study population (10 cases/100 person-years) –Concentrated among patients with history of depressive disorders at baseline  Age and history of depressive disorders significantly predicted depressive episode during treatment